Pharma Focus Asia

Sandoz Discovered First-of-its-kind Tyruko® Biosimilar for Multiple Sclerosis

Sandoz has introduced first-of-its-kind Tyruko® (natalizumab-sztn) biosimilar designed specifically for the treatment of relapsing forms of multiple sclerosis. 

Tyruko is the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis. Tyruko has been developed to exhibit a remarkably close resemblance to the reference medication, which happens to be a well-established and highly efficient disease-modifying treatment for relapsing forms of multiple sclerosis

This reference medicine is an anti-α4 integrin monoclonal antibody, recognised for its effectiveness in managing the condition.

In the United States, Tyruko has received approval for use as a standalone therapy to treat various forms of multiple sclerosis, encompassing clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive disease. Furthermore, it is also indicated for the treatment of Crohn’s disease in adult patients. 

Tyruko closely mirrors the reference medicine in terms of its intravenous (IV) dosage form, route of administration, dosing regimen, and presentation.

Biosimilars are an important treatment option as they have no clinically meaningful differences from their reference medicines. Prescribing biosimilars enhances access to affordable medications, improves adherence, and contributes to controlling healthcare costs.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024